QT prolongation and Torsades de Pointes in patients previously treated with Anthracyclines

Anti-Cancer Drugs

Volumn 18, Issue 4, 2007, Pages 493-498

  Arbel, Yaron ^a   Swartzon, Michael ^a   Justo, Dan ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anthracycline; QT interval; Torsades de Pointes

Indexed keywords

ACLARUBICIN; ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; IDARUBICIN; MITOXANTRONE; PYRROLE DERIVATIVE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DRUG INDUCED DISEASE; FEMALE; HEART LEFT VENTRICLE FAILURE; HODGKIN DISEASE; HUMAN; HYPOKALEMIA; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; TORSADE DES POINTES; CASE REPORT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; ELECTROCARDIOGRAPHY; ENDOMETRIUM TUMOR; LONG QT SYNDROME; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ELECTROCARDIOGRAPHY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LONG QT SYNDROME; MIDDLE AGED; MITOXANTRONE; RISK FACTORS; TORSADES DE POINTES;

EID: 34247580900     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328012d023     Document Type: Article

References (38)

1. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350:1013-1022.
2. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341:857-865.
3. Tsuji Y, Opthof T, Kamiya K, Yasui K, Liu W, Lu Z, et al. Pacing-induced heart failure causes a reduction of delayed rectifier potassium currents along with decreases in calcium and transient outward currents in rabbit ventricle. Cardiovasc Res 2000; 48:300-309.
4. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004; 22:1864-1871.
5. Pinarli FG, Oguz A, Tunaoglu FS, Karadeniz C, Gokcora N, Elbeg S. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005; 44:370-377.
6. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003; 97:1991-1998.
7. Milberg P, Fleischer D, Stypmann J, Osada N, Monnig G, Engelen MA, et al. Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by I(Kr) blockers. Basic Res Cardiol 2007; 102:42-51.
8. Bagatell R, Hainstock M, Lowe MC, Barber BJ, Samson RA. The perfect storm: torsades de pointes in a child with leukemia. Pediatr Blood Cancer 2005; (in press).
9. Sisakova M, Toman O, Florianova A, Kadlecova J, Chroust K, Papousek I, et al. Extension of QT interval as a consequence of risk factor accumulation - case study. Vnitr Lek 2006; 52:271-273.
10. Tsuda N, Oka R, Kajino H, Kajino M, Okuno A. Sudden death of a patient in complete remission after anthracycline therapy for acute lymphoblastic leukemia. Pediatr Int 2000; 42:319-321.
11. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98:266-271.
12. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000; 133:881-885.
13. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995; 24:352-361.
14. Patel SP, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovek S, Kantarjian H, et al. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia. Leuk Res 2006; 30:362-363.
15. Wortman JE, Lucas VS Jr, Schuster E, Thiele D, Logue GL. Sudden death during doxorubicin administration. Cancer 1979; 44:1588-1591.
16. Morioka M, Kakinoki Y, Katagiri M, Iwasaki H, Gotohda Y, Kobayashi T, et al. Torsade de pointes ventricular tachycardia in a patient with acute myelocytic leukemia. Rinsho Ketsueki 1991; 32:1009-1011.
17. Stupp R, Bauer J, Pagani O, Gerard B, Cerny T, Sessa C, et al. Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Ann Oncol 1998; 9:1233-1242.
18. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270:2590-2597.
19. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983; 2:806-817.
20. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes. Mechanisms and management. Drugs 1994; 47:51-65.
21. Nanavati KA, Fisher SD, Miller TL, Lipshultz SE. HIV-related cardiovascular disease and drug interactions. Am J Cardiovasc Drugs 2004; 4:315-324.
22. Houltz B, Darpo B, Edvardsson N, Blomstrom P, Brachmann J, Crijns HJ, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 1998; 21:1044-1057.
23. Bazzet HC. An analysis of time relations of echocardiograms. Heart 1920; 7:353-367.
24. Naito K, Kobayashi M, Sahara N, Shigeno K, Nakamura S, Shinjo K, et al. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy. Int J Hematol 2006; 83:318-323.
25. Kishi S, Yoshida A, Yamauchi T, Tsutani H, Lee JD, Nakamura T, et al. Torsade de pointes associated with hypokalemia after anthracycline treatment in a patient with acute lymphocytic leukemia. Int J Hematol 2000; 71:172-179.
26. Tatetsu H, Asou N, Nakamura M, Hanaoka N, Matsuno F, Horikawa K, et al. Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia. Am J Hematol 2006; 81:366-369.
27. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97:1514-1516.
28. Otsuka M, Kanamori H, Sasaki S, Taguchi J, Harano H, Ogawa K, et al. Torsades de pointes complicating pentamidine therapy of pneumocystis carinii pneumonia in acute myelogenous leukemia. Intern Med 1997; 36:705-708.
29. Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis 2004; 39:e49-e52.
30. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17:3333-3355.
31. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med 1978; 65:823-832.
32. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23:7685-7696.
33. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89:942-949.
34. Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999; 3:145-159.
35. Isner JM, Ferrans VJ, Cohen SR, Witkind BG, Virmani R, Gottdiener JS, et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol 1983; 51:1167-1174.
36. Kelso EJ, Geraghty RF, McDermott BJ, Cameron CH, Nicholls DP, Silke B. Characterisation of a cellular model of cardiomyopathy, in the rabbit, produced by chronic administration of the anthracycline, epirubicin. J Mol Cell Cardiol 1997; 29:3385-3397.
37. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332:1738-1743.
38. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-717.